Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

[Low-grade serous ovarian carcinoma: A retrospective study on 34 complete cytoreductive surgeries].

Gynecologie, obstetrique, fertilite & senologie·2021

Same author

[Immunotherapy for locally advanced and metastasized bladder cancer].

Der Urologe. Ausg. A·2018

Same author

[Minimally invasive vs. open partial nephrectomy : Perioperative success and complication rates].

Der Urologe. Ausg. A·2018

Same author

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).

European urology focus·2018

Same author

Functional Outcome of Completely Intracorporeal Robotic Ileal Ureteric Replacement.

Urology·2017

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

See all related articles

Search research articles

Related Experiment Video

Updated: May 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Castration-resistant prostate cancer (CRPC)].

W Loidl¹, F Luger, A Roosen

¹Urologische Abteilung, Krankenhaus der Barmherzigen Schwestern, Seilerstätte 4, A-4010, Linz, Österreich, wolfgang.loidl@bhs.at.

Der Urologe. Ausg. A

|March 12, 2014

Summary

This summary is machine-generated.

Castration-resistant prostate cancer understanding has advanced, offering new treatments to extend life and improve quality of life. Further research is needed for treatment response evaluation and molecular markers.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: May 2, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

Oncology
Urology

Context:

The understanding of castration-resistant prostate cancer (CRPC) has significantly evolved recently.
CRPC is now clearly defined with distinct disease patterns.
Numerous novel therapeutic agents are available to prolong patient survival and enhance quality of life.

Purpose:

To provide an overview of the current advancements in castration-resistant prostate cancer management.
To highlight the importance of understanding pharmacodynamics and side effects of new agents.
To emphasize the need for continuous education for urologists in managing CRPC.

Summary:

Recent progress has refined the definition and understanding of castration-resistant prostate cancer.
New effective treatments are available, improving patient lifespan and quality of life.
Understanding drug mechanisms and side effects is crucial for effective clinical application.

Impact:

Improved patient outcomes through advanced treatment options for CRPC.
Highlights the necessity for ongoing professional development in urology.
Identifies areas for future research, including treatment response evaluation and molecular marker development.